Nine severe TEAEs (arrhythmia, pancreatitis, fatigue, pain, bile duct stone, alanine transaminase [ALT] increased, aspartate transaminase [AST] increased, joint swelling, and weight-bearing difficulty) were experienced by three patients (8.1%) in the switch group, none of which were deemed to be IARs or related to the study drug treatment. The gene discussed is GPT; the disease is Arrhythmia.